Stock 5EA ELANCO ANIMAL HEALTH INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Elanco Animal Health Incorporated Deutsche Boerse AG

Equities

5EA

US28414H1032

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 02:05:10 2024-05-28 am EDT 		5-day change 1st Jan Change
15.34 EUR -0.13% Intraday chart for Elanco Animal Health Incorporated -1.29% +16.02%
May. 28 US FDA approves Elanco's feed ingredient to cut methane emissions in dairy cows RE
May. 28 Elanco Says FDA Confirms Bovaer Meets Safety, Efficacy Requirements MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,985 14,474 13,427 5,795 7,343 8,297 - -
Enterprise Value (EV) 1 13,006 20,106 19,108 11,350 12,765 13,071 12,574 12,043
P/E ratio 164 x -24.1 x -29.3 x -81.5 x -5.96 x -408 x 71.9 x 35.3 x
Yield - - - - - - - -
Capitalization / Revenue 3.58 x 4.42 x 2.82 x 1.31 x 1.66 x 1.85 x 1.77 x 1.69 x
EV / Revenue 4.24 x 6.14 x 4.01 x 2.57 x 2.89 x 2.91 x 2.68 x 2.45 x
EV / EBITDA 19.6 x 38 x 18.1 x 11.1 x 13 x 13.3 x 11.8 x 10.4 x
EV / FCF 155 x -114 x 53.5 x 36 x 97.4 x 30.2 x 15.9 x 16.6 x
FCF Yield 0.64% -0.87% 1.87% 2.78% 1.03% 3.31% 6.29% 6.03%
Price to Book 1.98 x 1.71 x 1.78 x 0.77 x 1.18 x 1.4 x 1.37 x 1.34 x
Nbr of stocks (in thousands) 373,004 471,915 473,099 474,205 492,798 494,182 - -
Reference price 2 29.45 30.67 28.38 12.22 14.90 17.14 17.14 17.14
Announcement Date 2/19/20 2/24/21 2/24/22 2/21/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,071 3,273 4,765 4,418 4,417 4,490 4,688 4,911
EBITDA 1 662.8 528.5 1,057 1,023 979 982.2 1,068 1,160
EBIT 1 548.8 213.5 922 918 876 851.1 943.7 1,029
Operating Margin 17.87% 6.52% 19.35% 20.78% 19.83% 18.96% 20.13% 20.96%
Earnings before Tax (EBT) 1 - - - - - 1,247 1,463 -
Net income 1 67.9 -560.1 -472 -74 -1,231 -27.55 52.06 141.5
Net margin 2.21% -17.11% -9.91% -1.67% -27.87% -0.61% 1.11% 2.88%
EPS 2 0.1800 -1.270 -0.9700 -0.1500 -2.500 -0.0420 0.2383 0.4850
Free Cash Flow 1 83.7 -175.6 357 315 131 432.5 790.4 726.5
FCF margin 2.73% -5.36% 7.49% 7.13% 2.97% 9.63% 16.86% 14.79%
FCF Conversion (EBITDA) 12.63% - 33.77% 30.79% 13.38% 44.04% 74.01% 62.64%
FCF Conversion (Net income) 123.27% - - - - - 1,518.38% 513.43%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/19/20 2/24/21 2/24/22 2/21/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,113 1,225 1,177 1,028 988 1,257 1,057 1,068 1,035 1,205 1,153 1,085 1,058 1,239 1,184
EBITDA 1 212 339 300 205 174 379 222 214 165 294 255.6 218.8 217.8 313.4 273
EBIT 1 180 315 284 180 157 354 210 183 148 271 222.5 185.3 176.1 295.2 241.4
Operating Margin 16.17% 25.71% 24.13% 17.51% 15.89% 28.16% 19.87% 17.13% 14.3% 22.49% 19.3% 17.08% 16.65% 23.82% 20.39%
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income 1 -97 48 -22 -49 -54 103 -97 -1,096 -141 32 3.6 -27.65 -22.45 46 7
Net margin -8.72% 3.92% -1.87% -4.77% -5.47% 8.19% -9.18% -102.62% -13.62% 2.66% 0.31% -2.55% -2.12% 3.71% 0.59%
EPS 2 -0.2000 0.1000 -0.0400 -0.1000 -0.1100 0.2100 -0.2000 -2.220 -0.2900 0.0600 0.0125 -0.0500 -0.0650 0.0850 0.0200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/24/22 5/9/22 8/8/22 11/8/22 2/21/23 5/9/23 8/7/23 11/7/23 2/26/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,021 5,632 5,681 5,555 5,422 4,774 4,277 3,746
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.049 x 10.66 x 5.375 x 5.43 x 5.538 x 4.86 x 4.004 x 3.23 x
Free Cash Flow 1 83.7 -176 357 315 131 433 790 727
ROE (net income / shareholders' equity) 7.33% 2.95% 6.42% 7.41% 6.5% 7.8% 8.6% 9.12%
ROA (Net income/ Total Assets) 4.39% 1.55% 3.01% 3.43% 2.94% 3.22% 3.85% 4.35%
Assets 1 1,546 -36,145 -15,692 -2,159 -41,855 -856.4 1,353 3,254
Book Value Per Share 2 14.90 18.00 15.90 15.90 12.60 12.30 12.50 12.80
Cash Flow per Share 2 0.6100 -0.0900 0.9900 0.9300 0.5500 1.280 1.570 1.780
Capex 1 140 135 126 137 140 190 202 209
Capex / Sales 4.57% 4.11% 2.64% 3.1% 3.17% 4.23% 4.3% 4.26%
Announcement Date 2/19/20 2/24/21 2/24/22 2/21/23 2/26/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Elanco Animal Health Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
17.14 USD
Average target price
19.11 USD
Spread / Average Target
+11.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

1st Jan change Capi.
ZOETIS INC. Stock Zoetis Inc.
-13.21% 77.6B
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+24.62% 3.72B
VIRBAC Stock Virbac
-2.09% 3.27B
VIMIAN GROUP AB Stock Vimian Group AB
+14.02% 1.65B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-10.96% 1.56B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-24.54% 1.29B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-15.65% 1.14B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-5.25% 1.02B
PULIKE BIOLOGICAL ENGINEERING, INC. Stock Pulike Biological Engineering, Inc.
-15.14% 985M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. ELAN Stock
  4. 5EA Stock
  5. Financials Elanco Animal Health Incorporated